Phospholipase A2 Receptor, Immunofluorescence, Serum
Use
This test is useful for distinguishing primary from secondary membranous nephropathy in patients with low levels of anti-phospholipase A2 receptor (PLA2R) antibodies. It can be used for screening for anti-PLA2R antibodies and for monitoring patients with membranous nephropathy who have very low antibody titers. The presence of anti-PLA2R antibodies is highly specific for the diagnosis of primary membranous nephropathy, and 70% to 75% of patients with primary membranous nephropathy are positive for anti-PLA2R.
Special Instructions
Not provided.
Limitations
This test should not be used as a stand-alone test. A diagnosis of primary or secondary membranous nephropathy should not be based solely on this test result. Clinical symptoms, results from physical examinations, and other laboratory tests should be considered when diagnosing primary versus secondary membranous nephropathy. The absence of circulating anti-PLA2R autoantibodies does not rule out primary membranous nephropathy. Specimen issues such as gross hemolysis may cause the specimen to be rejected. Gross lipemia is acceptable, however.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
Anti-PLA2R
Protein
LOINC Codes
- 82991-1 - PLA2R IgG SerPl Ql IF
- 82991-1 - PLA2R IgG SerPl Ql IF
Result Turnaround Time
3-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial within 2 hours of collection. Preferred collection container is serum gel, acceptable is red top.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 14 days |
| Frozen | 14 days |